• chemical synoviorthesis;
  • children;
  • chronic synovitis;
  • haemophilia;
  • haemophilic arthropathy;
  • oxytetracycline

Summary.  Synoviorthesis is already widely used in the treatment of chronic haemophilic synovitis. The aim of this study was evaluate the effectiveness of oxytetracicline synoviorthesis on the frequency of haemarthrosis in haemophilic children with chronic synovitis and its impact on joint function. Between January 2001 and October 2006, we performed 34 synoviorthesis in 28 paediatric patients (6–16 years old) with diagnosis of haemophilic arthropathy stage I–II. At each joint were administered five doses of oxytetracycline for five consecutive weeks at doses of 100 mg in elbow and ankle and 250 mg in the knee. The frequency of haemarthrosis and range of joint mobility were evaluated before and after of treatment. The results were analysed with Student t-test and descriptive statistics. Thirty-four joints were treated, including 20 knees (58.8%), eight elbows (23.5%) and six ankles (17.6%). Median follow-up was 46.3 months (range 12–71 months). The frequency of haemarthrosis was recorded before treatment 47.3 year−1 (range 12–96, < 0.0001) and decreased to 3.5 year−1 (range 0–15, = 0.0119) after treatment. The range of joint motion in flexion–extension before treatment was 84.9°, while after this was 97.5° (= 0.0119). The synoviorthesis with oxytetracycline has shown a favourable effect in the treatment of chronic haemophilic synovitis in reducing the frequency of haemarthrosis and improvement was observed consistently in the range of motion.